Skip to main content
PMC home page
Gut logoLink to Gut
. 1994 Sep;35(9):1155–1158. doi: 10.1136/gut.35.9.1155

New salicylates as maintenance treatment in ulcerative colitis.

G Järnerot 1
PMCID: PMC1375685  PMID: 7959217

Full text

PDF
1155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 1972 Jan 15;1(5793):152–154. doi: 10.1136/bmj.1.5793.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  5. Chan R. P., Pope D. J., Gilbert A. P., Sacra P. J., Baron J. H., Lennard-Jones J. E. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609–615. doi: 10.1007/BF01299921. [DOI] [PubMed] [Google Scholar]
  6. Courtney M. G., Nunes D. P., Bergin C. F., O'Driscoll M., Trimble V., Keeling P. W., Weir D. G. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 1992 May 23;339(8804):1279–1281. doi: 10.1016/0140-6736(92)91601-4. [DOI] [PubMed] [Google Scholar]
  7. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dwarakanath A. D., Michael J., Allan R. N. Sulphasalazine induced renal failure. Gut. 1992 Jul;33(7):1006–1007. doi: 10.1136/gut.33.7.1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eliakim R., Wengrower D., Ligumsky M., Rachmilewitz D. Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission. Isr J Med Sci. 1990 Jan;26(1):47–49. [PubMed] [Google Scholar]
  11. Ewe K., Press A. G., Bollen S., Schuhn I. Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector. Dig Dis Sci. 1991 Feb;36(2):146–152. doi: 10.1007/BF01300748. [DOI] [PubMed] [Google Scholar]
  12. Giaffer M. H., Holdsworth C. D., Lennard-Jones J. E., Rodrigues C. A., McIntyre P. B., Manjunatha S., Baron J. H., Barrison I. G., Polson R. J., Hoare A. M. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992 Aug;6(4):479–485. doi: 10.1111/j.1365-2036.1992.tb00561.x. [DOI] [PubMed] [Google Scholar]
  13. Giaffer M. H., O'Brien C. J., Holdsworth C. D. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992 Feb;6(1):51–59. doi: 10.1111/j.1365-2036.1992.tb00544.x. [DOI] [PubMed] [Google Scholar]
  14. Green J. R., Swan C. H., Rowlinson A., Gibson J. A., Brown P., Kerr G. D., Swarbrick E. T., Thornton P. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992 Oct;6(5):647–652. doi: 10.1111/j.1365-2036.1992.tb00578.x. [DOI] [PubMed] [Google Scholar]
  15. Ireland A., Mason C. H., Jewell D. P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988 Jun;29(6):835–837. doi: 10.1136/gut.29.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Järnerot G. Clinical tolerance of olsalazine. Scand J Gastroenterol Suppl. 1988;148:21–23. doi: 10.3109/00365528809101542. [DOI] [PubMed] [Google Scholar]
  17. Kiilerich S., Ladefoged K., Rannem T., Ranløv P. J. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut. 1992 Feb;33(2):252–255. doi: 10.1136/gut.33.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McIntyre P. B., Rodrigues C. A., Lennard-Jones J. E., Barrison I. G., Walker J. G., Baron J. H., Thornton P. C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther. 1988 Jun;2(3):237–243. doi: 10.1111/j.1365-2036.1988.tb00693.x. [DOI] [PubMed] [Google Scholar]
  19. Mulder C. J., Tytgat G. N., Weterman I. T., Dekker W., Blok P., Schrijver M., van der Heide H. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988 Dec;95(6):1449–1453. doi: 10.1016/s0016-5085(88)80061-1. [DOI] [PubMed] [Google Scholar]
  20. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  21. Rijk M. C., van Schaik A., van Tongeren J. H. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992 Oct;27(10):863–868. doi: 10.3109/00365529209000155. [DOI] [PubMed] [Google Scholar]
  22. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  23. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989 Apr;3(2):183–191. [PubMed] [Google Scholar]
  24. Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986 Apr;90(4):1024–1030. doi: 10.1016/0016-5085(86)90882-6. [DOI] [PubMed] [Google Scholar]
  25. Sandberg-Gertzén H., Ryde M., Järnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol. 1983 Jan;18(1):107–111. doi: 10.3109/00365528309181568. [DOI] [PubMed] [Google Scholar]
  26. Schröder H., Lewkonia R. M., Price Evans D. A. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital. Clin Pharmacol Ther. 1973 Sep-Oct;14(5):802–809. doi: 10.1002/cpt1973145802. [DOI] [PubMed] [Google Scholar]
  27. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. doi: 10.7326/0003-4819-118-7-199304010-00009. [DOI] [PubMed] [Google Scholar]
  29. Watson B. W., Meldrum S. J., Riddle H. C., Brown R. L., Sladen G. E. pH profile of gut as measured by radiotelemetry capsule. Br Med J. 1972 Apr 8;2(5805):104–106. doi: 10.1136/bmj.2.5805.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wright J. P., O'Keefe E. A., Cuming L., Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci. 1993 Oct;38(10):1837–1842. doi: 10.1007/BF01296107. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES